No Data
No Data
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Catapults 33% Though Its Price And Business Still Lag The Industry
BTIG Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $5
BTIG analyst Julian Harrison maintains $Akebia Therapeutics(AKBA.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 48.2% and
Buy Rating Justified by Akebia Therapeutics' Strengthened Dialysis Negotiations and Positive Commercial Prospects
Sector Update: Health Care Stocks Advance Premarket Thursday
Akebia Regains Full Rights to Sell Vafseo Tablets in US After Ending Licensing Deal With CSL Vifor
Akebia Regains Full Rights to Kidney Disease Therapy From CSL
No Data